Dr. Tchistiakova is currently Senior Director at BioMedicine Design (BMD) department of Pfizer leading multifunctional group focused on the discovery of human therapeutic antibodies, antibody humanization, optimization and biotherapeutic formats engineering including bi-, tri-specifics and T cell retargeting efforts. She also oversees a large portfolio of biotherapeutic programs from initiations to IND in collaborations with Oncology, Center of Therapeutic Innovation and Inflammation & Immunity research units of Pfizer, eight of these programs progressed to clinical development including anti-myostatin mAb RK35, anti-IL-13 mAb IMA-638, anti-A-beta mAb AAB-03, anti-P-cadherin CD3 bispecific, 5T4 ADC, Notch3ADC, GD3 ADC and NG Her2 ADC.
Prior to Pfizer, Dr. Tchistiakova worked for 8 years at Wyeth Research where she progressed from Principal Scientist III to Director level by leading generation of biotherapeutics on more than 15 programs using rodent hybridoma, human phage display libraries platforms and co-lead several external collaborations.
Dr Tchistiakova also held the position of Section Head at Albany Molecular Research Inc., where she led internal and collaborative Drug Screening Programs using company`s natural product libraries and was also one of the co-founders of Supratek Pharma Inc. in Montreal, Canada where she held Senior Scientist and Group Leader positions from 1995 to 2001 and was responsible for targeted drug delivery efforts. Dr. Tchistiakova received her Ph.D degree in Biochemistry from the Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
Dr. Tchistiakova has coauthored of over 50 scientific publications, book chapters and patents.
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October